News / Insights

News & Blog

Regulatory updates. Practical perspectives.
A clearer view of what comes next.

Blog: Blog2

One Sunscreen Could Land You on FDA's Blacklist — Have You Checked Your OMUFA FY2026 Status?

"Our product is a cosmetic — it just has an SPF rating." "Anti-dandruff shampoo is regulated as a drug?" If these questions sound familiar, your facility may already be at risk. You May Be Selling a Drug Without Knowing It The FDA classifies the following products not as cosmetics, but as OTC (over-the-counter) drugs : Sunscreens with SPF claims Acne products containing salicylic acid or benzoyl peroxide Anti-dandruff shampoos containing zinc pyrithione or selenium sulfide To

FDA News

Provision Consulting Group

Mar 132 min read

FDA Acne Product Recall: What Manufacturers Need to Know About Benzene Contamination

April 21, 2025 In the latest FDA acne product recall, certain acne treatments were pulled from the shelves after testing revealed benzene...

FDA News

Provision Consulting Group

Apr 21, 20252 min read

Why FDA New Drug Applications Are Expensive and Time-Consuming: Navigating the Long Road to Approval

October 16, 2024 When it comes to bringing a new drug to market, the hurdles of the FDA New Drug Application (NDA) process are immense....

FDA Regulatory Insights

Provision Consulting Group

Oct 16, 20243 min read

FDA Finalizes Mandatory Cosmetics Recall Guidance: What K-Beauty Brands Entering the U.S. Should Know

2 days ago

Renew Your FDA Initial Importer Designation with Provision

Oct 16

OTC Drug Establishment Renewal: Time to Renew with Provision

Oct 16

FDA Food Facility Registration: 2026 Is a Renewal Year

Oct 14

FY2027 FDA Medical Device Registration Renewal: It’s Time to Renew with Provision

Oct 14

FDA’s FY2027 Medical Device Guidance Agenda: What Could It Mean for 510(k) Manufacturers?

Oct 7

Provision CEO Sung Kwon to Speak at Cosmoprof Asia Hong Kong 2026

Oct 2

FDA’s Purolea Warning Letter: What AI-Assisted GMP Documentation Means for Manufacturers

Sep 23

FDA Form 483 Response Is Not the Finish Line: What the Bausch & Lomb Warning Letter Reveals About CAPA

Sep 19

FDA Sunscreen Regulatory Update: PABA and Trolamine Salicylate Removed from OTC Monograph M020

Sep 16

What Does It Mean When Torriden Delegates U.S. Regulatory Compliance to Provision Consulting Group?

Sep 9

Introducing the Provision Client Portal (Beta): A New Way to Work With Us

Sep 9

Why Provision Built R.I.S.E. Turning 50,000+ Real Regulatory Cases into Regulatory Intelligence

Aug 28

FY2027 FDA Medical Device User Fees Finalized: MDUFA V’s Final Year and What You Need to Know

Aug 24

Provision Consulting Group Speaks at ACI Conference on K-Beauty and U.S. Regulatory Challenges

Aug 18

MDUFA VI: Why FDA Device Reviews Are Getting Tougher, Not Faster

Aug 14

Trapped in Customs: The Hidden Triggers Behind FDA Import Alerts for Medical Devices

Aug 3

Container Stuck at a U.S. Port — What Triggers an FDA Import Alert for Food and Supplements

Jul 27

FDA US Agent: What Happens When They Go Silent — and You Picked Them on Price

Jul 20

What Huons' FDA Warning Letter Reveals About Today's CGMP Enforcement

Jun 30

FDA 510(k) Clearance: Why a "Complete" eSTAR Doesn’t Guarantee Approval

Jun 29

FDA Sunscreen Ingredient Update: Bemotrizinol Added to the U.S. OTC Monograph

Jun 23

A Kimchi Brand Just Got Recalled. The Culprit? Anchovies.

Jun 15

KOTRA x Provision Consulting Group to Support Korean Companies at BIO International Convention San Diego

Jun 11

The FDA is Cracking Down on Sunscreen Factories—Is Yours Truly Ready?

Jun 1

FDA-Compliant, Yet Still Sued? The Labeling Risks U.S.-Bound Brands Often Miss

May 15

Medical Devices Have IDs Too — The FDA UDI Guide for U.S. Market Entry

May 4

MoCRA Insight: Same Ingredients, Same Formula — Different FDA Interpretations

Apr 24

Longevity and In & Out Beauty: What K-Beauty Brands Are Missing in the U.S. Market

Apr 13

'Magnif's make p:rem', a K-Beauty Brand, Just Landed at Sephora. Here's What Made It Possible.

Mar 31

Why Your K-Clinic Launch Could Trigger an FDA "Drug Claim" — MoCRA Strategies for 2026

Mar 24

One Sunscreen Could Land You on FDA's Blacklist — Have You Checked Your OMUFA FY2026 Status?

Mar 13

Two More Digits. A Lot More Work. — FDA's NDC Format Change Explained

Mar 6

K-Beauty FDA Compliance: Why 'Marketing' Is No Longer Enough in the U.S. Market

Feb 24

[Cosmoprof Miami 2026] K-Beauty: Moving Beyond ‘Registration’ to ‘Regulatory Strategy’

Feb 16

The K-Beauty "Inner Beauty" Paradox: Why Your Best Marketing is Your Biggest Risk in the U.S.

Jan 30

2 3 4 5

From insight to action

What does this mean for your business?

Talk through your FDA questions with a team that stays close to the details.

Start a conversation ↗

REGULATORY SERVICES

MARKET ENTRY

News & Blog

One Sunscreen Could Land You on FDA's Blacklist — Have You Checked Your OMUFA FY2026 Status?

FDA Acne Product Recall: What Manufacturers Need to Know About Benzene Contamination

Why FDA New Drug Applications Are Expensive and Time-Consuming: Navigating the Long Road to Approval

FDA Finalizes Mandatory Cosmetics Recall Guidance: What K-Beauty Brands Entering the U.S. Should Know

Renew Your FDA Initial Importer Designation with Provision

OTC Drug Establishment Renewal: Time to Renew with Provision

FDA Food Facility Registration: 2026 Is a Renewal Year

FY2027 FDA Medical Device Registration Renewal: It’s Time to Renew with Provision

FDA’s FY2027 Medical Device Guidance Agenda: What Could It Mean for 510(k) Manufacturers?

Provision CEO Sung Kwon to Speak at Cosmoprof Asia Hong Kong 2026

FDA’s Purolea Warning Letter: What AI-Assisted GMP Documentation Means for Manufacturers

FDA Form 483 Response Is Not the Finish Line: What the Bausch & Lomb Warning Letter Reveals About CAPA

FDA Sunscreen Regulatory Update: PABA and Trolamine Salicylate Removed from OTC Monograph M020

What Does It Mean When Torriden Delegates U.S. Regulatory Compliance to Provision Consulting Group?

Introducing the Provision Client Portal (Beta): A New Way to Work With Us

Why Provision Built R.I.S.E. Turning 50,000+ Real Regulatory Cases into Regulatory Intelligence

FY2027 FDA Medical Device User Fees Finalized: MDUFA V’s Final Year and What You Need to Know

Provision Consulting Group Speaks at ACI Conference on K-Beauty and U.S. Regulatory Challenges

MDUFA VI: Why FDA Device Reviews Are Getting Tougher, Not Faster

Trapped in Customs: The Hidden Triggers Behind FDA Import Alerts for Medical Devices

Container Stuck at a U.S. Port — What Triggers an FDA Import Alert for Food and Supplements

FDA US Agent: What Happens When They Go Silent — and You Picked Them on Price

What Huons' FDA Warning Letter Reveals About Today's CGMP Enforcement

FDA 510(k) Clearance: Why a "Complete" eSTAR Doesn’t Guarantee Approval

FDA Sunscreen Ingredient Update: Bemotrizinol Added to the U.S. OTC Monograph

A Kimchi Brand Just Got Recalled. The Culprit? Anchovies.

KOTRA x Provision Consulting Group to Support Korean Companies at BIO International Convention San Diego

The FDA is Cracking Down on Sunscreen Factories—Is Yours Truly Ready?

FDA-Compliant, Yet Still Sued? The Labeling Risks U.S.-Bound Brands Often Miss

Medical Devices Have IDs Too — The FDA UDI Guide for U.S. Market Entry

MoCRA Insight: Same Ingredients, Same Formula — Different FDA Interpretations

Longevity and In & Out Beauty: What K-Beauty Brands Are Missing in the U.S. Market

'Magnif's make p:rem', a K-Beauty Brand, Just Landed at Sephora. Here's What Made It Possible.

Why Your K-Clinic Launch Could Trigger an FDA "Drug Claim" — MoCRA Strategies for 2026

One Sunscreen Could Land You on FDA's Blacklist — Have You Checked Your OMUFA FY2026 Status?

Two More Digits. A Lot More Work. — FDA's NDC Format Change Explained

K-Beauty FDA Compliance: Why 'Marketing' Is No Longer Enough in the U.S. Market

[Cosmoprof Miami 2026] K-Beauty: Moving Beyond ‘Registration’ to ‘Regulatory Strategy’

The K-Beauty "Inner Beauty" Paradox: Why Your Best Marketing is Your Biggest Risk in the U.S.

What does this mean for your business?